Introduction
============

Osteosarcoma (OS) is a rare bone cancer, which is derived from mesenchymal tissues and usually occurs in the long bones of the body such as the distal femur, proximal tibia, and humeral metaphysis. OS is one of the most common bone malignancies in children and adolescents, with an annual incidence of approximately 5/1,000,000, and it always has detectable metastases at diagnosis frequently leading to a poor prognosis generally [@B1]. Although the fundamental mechanism underlying the development of OS is still not well understood, previous studies have suggested that the development of OS is a complex, multistep and multifactorial process and many environmental and genetic factors are involved throughout the development of this cancer [@B2],[@B3]. However, not all individuals exposed to similar risk factors would develop OS, which suggests that genetic variations may influence OS susceptibility. Recently, many genome-wide association studies (GWASs) have reported some evidence related to genetic susceptibility of OS, and some results were consistently replicated in different studies [@B4],[@B5]. Although genetic association analysis has provided a promising approach to the genetics of complex diseases, such as psychiatry disorders [@B6]-[@B10], current results account for only a small percentage of the estimated heritability with the lack of their systematic biological interpretation [@B11]. Give of genetic heterogeneity existing in different populations, identifying individual candidate genes/variants with small effects on disease risks and follow-up studies are essential to confirm those findings and extend them [@B12].

During the past several years, molecular genetic studies have brought a wealth of new information of some susceptibility loci in chromosome 9 for multiple tumors, such as *CDKN2A/B* (cyclin-dependent kinase inhibitors 2A/B), *ANRIL* (antisense non coding RNA) and *MTAP*(methylthioadenosine phosphorylase), which are all involved in cell cycle, protein synthesis and tumors suppression [@B13]-[@B15]. The MTAP gene located at 9p21 is flanked by *CDKN2A* and *miR-31*, and the gene is frequently co-deleted with the *CDKN2A* and *CDKN2B*in many different tumors [@B16]-[@B19]. Moreover, Pasmant et al[@B20] found that the regulatory sequences, such as enhancers, were enriched in the region of 9p21.3, which can regulate the expression of genes (*MTAP-CDKN2A/2B/CDKN2BAS*/-*IFNα21*). *MTAP* is a ubiquitous enzyme that catalyzes the phosphorolysis of the nucleoside*MTA* (methylthioadenosine), which is generated during the synthesis of polyamines spermidine and spermine. In addition, it is also an essential enzyme in the salvage pathway of adenine and in methionine synthesis [@B21]-[@B23]. It has further been reported that the genetic polymorphisms of *MTAP* associated with some cancers including OS in Caucasians and ischemic stroke and myocardial infarction in Han Chinese population [@B24]-[@B27]. Loss of *MTAP*expression would exert a tumor-promoting effect, suggesting that *MTAP* may function as a tumor suppressor gene [@B28]-[@B30]. MTAP-deficient cells are reported to be more sensitive than MTAP-positive cells to inhibitors of de novo purine synthesis and to methionine deprivation [@B31],[@B32]. In MTAP-negative tumor cells, it has also been evidenced that conversion proceeds and the tumor cells can be selectively killed [@B31],[@B32].

Since *MTAP* has been linked closely with many tumors, *MTAP* has gained much attention among many candidate genes predisposing to OS. Because the underlying biological mechanisms of OS remain largely unknown, the contribution of *MTAP* to OS has not been elucidated, despite evidence of a strongly significant association within the Caucasian population. Thus, to improve the current understanding about the role of *MTAP* in the OS predisposition, it is necessary to investigate the consequences of genetic diversity in other ethnic populations. Currently, the role of *MTAP* in OS susceptibility in the Han Chinese population has not been previously evaluated. Therefore, we carried out the two-stage case-control study to further examine the associations between *MTAP* and the OS risk in Han Chinese individuals. The aim of the present study was to assess the relationship of common variants in *MTAP* with the increased risk of OS and provide clues as to the nature of the mechanisms involved in the etiology of OS.

Material and methods
====================

Study Subjects
--------------

A two-stage population-based case-control study was conducted. All of 284 OS cases and 981 healthy controls were recruited from 3 different hospitals (The First Affiliated Hospital of Xi\'an Jiaotong University, The Second Affiliated Hospital of Xi\'an Jiaotong University and Xi\'an Honghui Hospital) and designed as the discovery stage (the first stage) in this study. Subsequently, independent 108 patients with OS and 597 healthy controls additionally collected from another hospital (Xijing Hospital) were considered as the subjects of the validation stage (the second stage). All patients were histologically/pathologically confirmed by two experienced pathologists. All the healthy controls were recruited from the general health check-up centers in these hospitals, and they had been under the health screening. Each subject was interviewed using a standard questionnaire by a trained nurse to collect medical histories and demographic characteristics. The clinical characteristics of controls were matched to the gender and age distribution with the OS cases, as presented in Table [1](#T1){ref-type="table"}. All subjects were of Chinese Han ethnicity and recruited from the city of Xi\'an in Shaanxi Province (China) May 2010 to July 2015. Based on self-report and medical records regarding their own and their paternal grandparents\' place of birth, we excluded individuals or their three-generation families not born in Xi\'an. This study was performed in accordance with the ethical guidelines of the Declaration of Helsinki (version 2002) and was approved by the Xi\'an Jiaotong University Ethics Committee. All participants have written (signed) informed consent forms.

SNP selection and genotyping
----------------------------

We searched for SNPs with minor allele frequencies (MAF) over 0.01 between 10 kb upstream and 10 kb downstream of *MTAP* in the HapMap CHB database and found 45 SNPs. Afterwards, MAF ≥ 0.01 with pair-wise tagging and r^2^ ≥ 0.9 were used as the cutoff criteria during tag SNPs selection and resulted in 17 tag SNPs covering the region of *MTAP* for our study (Figure [1](#F1){ref-type="fig"}). Peripheral blood was drawn from a vein into a sterile tube containing ethylenediamine tetraacetic acid (EDTA), and the genomic DNA was isolated from peripheral blood leukocytes according to the manufacturer\'s protocol (Genomic DNA kit, Axygen Scientific Inc., California, USA). SNPs genotyping was performed at the Sequenom MassARRAY platform with the iPLEX GOLD chemistry (Sequenom, San Diego, CA, USA) based on the manufacturer\'s protocols. Briefly, SNPs were genotyped using high-throughput, matrix-assisted laser desorption ionization-time-of-flight (MALDI-TOF) mass spectrometry. Next, the resulting spectra were processed using Typer Analyzer software (Sequenom), and genotype data were generated from the samples [@B33]. As the final genotype call rate of each SNP exceeded 99.7% and the overall genotyping call rate reached 99.9%, further statistical analyses were considered to be reliable. For quality control, the status of both case and control samples was blind during all genotyping processes. Meanwhile, 5% of random samples were repeated and the results were 100% concordant.

Statistical analyses
--------------------

Student\'s *t* test and chi-square (χ^2^) test were conducted to analyze the differences in the distribution of characteristics between the OS patients and the healthy controls. Hardy-Weinberg equilibrium (HWE) for each SNP was estimated by using Haploview v4.2. Allelic and genotypic association tests were performed with the genetic analysis software Plink v1.9 and a logistic model was implemented for each SNP to investigate the association between genetic polymorphisms and OS risk. The Bonferroni correction was applied to address the multiple comparison problems and the strength of association between *MTAP* and OS risk was assessed by odds ratios (ORs) and 95% confidence intervals (CIs) from the logistic model with adjustments for age, gender and family history. For the single SNP association analyses, *P*-value was corrected using Bonferroni correction (corrected *P*-value = P × n, the number of SNPs). In addition to the single SNP association analyses, we also conducted haplotype-based analyses. The inter-marker relationship was determined by performing pair-wise linkage disequilibrium (LD) with Haploview v4.2. The haplotype frequencies were estimated by using GENECOUNTING v2.2. Besides, the haplotypic association analyses included a likelihood ratio test followed by permutation testing was performed for all haplotypes [@B34]. The Kaplan-Meier method was used to plot the OS curves. All tests were two-tailed, and a *P*-value of 0.05 was selected as a threshold for significance in all analyses.

Results
=======

Baseline characteristics of subjects
------------------------------------

A two-stage approach was utilized in our study, which included 392 OS patients and 1,578 healthy controls in both stages. Age, gender, cancer family history, tumor location, pathological fracture, metastasis and Enneking stage were summarized in Table [1](#T1){ref-type="table"}. In both stages, OS cases and healthy controls were matched by age with the mean age, and there were no significant differences regarding gender and family history between cases and controls (Table [1](#T1){ref-type="table"}). All OS cases were divided into some subgroups according to their tumor location, pathological fracture, metastasis and Enneking stage (Table [1](#T1){ref-type="table"}). In each stage, there were more patients with long tubular bones, metastasis and no pathological fracture, and the highest numbers of OS cases were in stage II, compared to stage I and III.

Allelic and genotypic association of SNPs with OS risk
------------------------------------------------------

Seventeen SNPs in *MTAP* were genotyped in the discovery dataset. The results of the single SNP-based association analyses of these SNPs in the discovery stage, including the Hardy-Weinberg equilibrium (HWE) test, were summarized in Tables [2](#T2){ref-type="table"} and Table [S1](#SM1){ref-type="supplementary-material"}. All genotype distributions among the subjects were in agreement with HWE (Table [2](#T2){ref-type="table"} and Table [S1](#SM1){ref-type="supplementary-material"}). We observed significant association signals for two SNPs (rs7023329 and rs7027989; adjusted *P* = 0.002908 and 0.04427, respectively), but it was only rs7023329 that still remained the association with OS risk after Bonferroni correction (Table [2](#T2){ref-type="table"}). Genotypic association analyses also confirmed the result of rs702339 with a similar pattern (adjusted *P* = 0.002885). The other 15 SNPs did not significantly differ in either allele or genotype distribution (Table [S1](#SM1){ref-type="supplementary-material"}).

Next, we performed single SNP association analyses for the two SNPs (rs7023329 and rs7027989) with 5 other surrounding SNPs (rs2165408, rs7871477, rs7867176, rs1544195 and rs7874112) in the validation dataset. The significant association of the SNP rs7023329 with OS risk was replicated (adjusted *P* = 0.006737) (Table [2](#T2){ref-type="table"}), indicating that the A allele was an OS risk allele, and the association with OS risk was still survival after Bonferroni correction (Table [2](#T2){ref-type="table"}). Moreover, genotypic association analyses also validated the conclusion (adjusted *P* = 0.007089). The allelic or genotype distributions of the other five SNPs did not significantly differ (Table [S1](#SM1){ref-type="supplementary-material"}). A similar positive effect of SNP on OS risk was further revealed by logistic regression regarding odds ratios (OR) and 95% confidence interval (CI) in both stages (Table [2](#T2){ref-type="table"}), after adjustments for age, gender and cancer family history.

Relationship between rs7023329 genotypes and clinicopathological characteristics
--------------------------------------------------------------------------------

The relationships between the associated SNP rs7023329 genotypes and clinicopathological parameters were evaluated, and the results were presented in Table [3](#T3){ref-type="table"}. However, there are not any obvious differences in the relations between age, gender, cancer family history, tumor location, pathological fracture, metastasis and Enneking stage, respectively, and rs7023329 genotypes in both stages (Table [3](#T3){ref-type="table"}).

Haplotypic association analyses
-------------------------------

To perform haplotype-based association analyses, we examined LD structure of 17 SNPs using the data from the discovery stage and identified three LD blocks, of which one block consisted of two SNPs (rs7023329 and rs7027989, Figure [2](#F2){ref-type="fig"}A). The LD block was also constructed in the validation stage (Figure [2](#F2){ref-type="fig"}B). Subsequent haplotypic association analyses were used to test the LD block mentioned above. As presented in Table [4](#T4){ref-type="table"}, significant *P* values (global *P* \< 0.0001, respectively) were obtained in both stages. Some haplotypes in the LD block were positively associated with OS risk. For example, the haplotype AA was significantly associated with OS as a risk haplotype. Because of the higher frequencies in healthy controls, the haplotype GG might protect against OS (Table [4](#T4){ref-type="table"}).

Analyses for the effect of rs7023329 on prognosis of OS patients
----------------------------------------------------------------

Significant association was observed between the rs7023329 and the overall survival of OS patients, and the rs7023329 may be therefore an independent prognostic factor for OS (Figure [3](#F3){ref-type="fig"}A). The survival analyses of rs7023329 indicated that OS patients carrying the AG+AA genotypes exhibited a worse survival rate compared with patients with the homozygous GG genotype (*P*= 0.017; Figure [3](#F3){ref-type="fig"}B). Patients with the AG+AA genotypes had a median survival time of 14.0 months, while patients with homozygote GG genotype had the best outcome (median survival time: 18.0 months).

Discussion
==========

The predominant hypothesis in recent years has been that the genetic architecture of OS involves several common variants of small effects and possibly also rare variants with much larger effects [@B35]. In our hospital-based case-control study, the role of common variants within MTAP gene in OS risk as well as the interaction of the associated SNP rs7023329 with clinical and demographic factors in the development of OS was assessed. The allele and genotype distributions of the SNP rs7023329 were significantly different between the case and control groups in two stages and the ORs and 95% CI also suggested the positive effects of the associated SNP on OS risk. Indeed, analyses of only some SNPs are not sufficient to draw a conclusion [@B36]. Our haplotype analyses also evidenced that the rs7023329 was significantly associated with OS. These results indicated that rs7023329 may be involved in susceptibility to the disease with an increased risk of OS. To the best of our knowledge, it is the first study to investigate the possible role of the SNP rs7023329 as a risk factor for OS and find the relationship between *MTAP* variations and susceptibility to OS development in the Han Chinese population.

To date, inaugural mechanism of OS was considered as a complex process and was not clear, but it was universally acknowledged that environment carcinogens could induce genomic polymorphism. It was reported that *MTAP* had a broad expression profile in the mammalian and was a key enzyme in the methionine salvage pathway [@B24],[@B37]. Loss of *MTAP* expression can exert a tumor promoting effect, suggesting that *MTAP* may function as a tumor suppressor gene [@B21],[@B30],[@B31],[@B38]. Moreover, the genetic polymorphism of *MTAP* was also considered as one of the potential genetic factors in various tumors [@B29],[@B39]-[@B41]. However, the exact mechanism by which the *MTAP* genetic polymorphisms affect the susceptibility of OS remains elusive. In our study, given the potential effect of the LD block on regulating gene transcription, we hypothesized that certain SNPs might influence the expression of *MTAP* in an unpredicted manner. Alternatively, the SNP rs7023329 might coexist in LD with certain undiscovered variants and participate with their regulation machinery to confer a risk for OS. No experimental evidence validates this hypothesis, and future functional studies are warranted to clarify this point. Multiple lines of evidence support that our results are unlikely to be artificial. First, significant signals were captured by both single SNP and haplotype-based analysis in two independent datasets. Second, the problem of population stratification has been avoided, as all samples of Han descent are from the same geographical region and there is no migration history for all subjects within their three previous generations. Moreover, the SNP rs7023329 in *MTAP* has been recently found to strongly associate with OS risk in Caucasians [@B26]. Similar conclusions were reached in two different ethnic populations (Han Chinese and Caucasian), reaffirming the association of *MTAP* with OS susceptibility.

Although our results raised the possibility that common variants in the *MTAP* are involved in the development of OS, several limitations should be noted in the present study. First, the hospital-based case-control study design often produced selection biases and information biases. The subjects may not be representative of the general population. However, geographic region is a good proxy for genetic matching in the Han Chinese population. Therefore, population stratification may be effectively avoided in our study because of samples from the same geographical region [@B42],[@B43]. Second, the relative small sample size might miss some weak gene-disease association and gene-environment interactions. Last, functional experiments are necessary to clarify the underlying molecular mechanisms of the association signal between the SNP rs7023329 within MTAP and OS in the future, and many unmeasured environmental and genetic factors also need to be taken into account in future studies. Therefore, all of our findings should be considered preliminary, and additional follow-up studies are required to confirm these results in other ethnic populations.

In summary, our two-stage case-control study indicates *MTAP* is a susceptible gene for OS risk in the Han Chinese population. A strong association between SNP rs7023329 and OS risk was revealed through several sets of analyses in two stages. Further functional studies would be desired to uncover fundamental characteristics of pathogenic mutations and to clarify the exact effect of *MTAP* on OS development, which could facilitate potential applications in the clinic.
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###### 

Distributions of selected variables in osteosarcoma patients and healthy controls.

  Variables               The Discovery Stage   *P*-value     The Validation Stage   *P*-value                     
  ----------------------- --------------------- ------------- ---------------------- -------------- -------------- -------
  Mean age (years)        21.00±4.7             21.02±4.3     0.956                  21.25 (±5.4)   21.26 (±5.0)   0.990
  ≤20                     165                   563           0.832                  61             340            0.928
  \>20                    119                   418                                  47             257            
  Gender                                                                                                           
  Male                    146 (51.4%)           498 (50.8%)   0.848                  56 (51.9%)     308 (51.6%)    0.960
  Female                  138 (48.6%)           483 (49.2%)                          52 (48.1%)     289 (48.4%)    
  Cancer family history                                                                                            
  Yes                     203 (71.5%)           685 (69.8%)   0.592                  70 (64.8%)     381 (63.8%)    0.843
  No                      81 (28.5%)            296 (30.2%)                          38 (35.2%)     216 (36.2%)    
  Tumor location                                                                                                   
  Long tubular bones      231 (81.3%)                                                83 (76.9%)                    
  Axial skeleton          53 (18.7%)                                                 25 (23.1%)                    
  Pathological fracture                                                                                            
  Yes                     55 (19.4%)                                                 23 (21.3%)                    
  No                      229 (80.6%)                                                85 (78.7%)                    
  Metastasis                                                                                                       
  Yes                     89 (31.3%)                                                 31 (28.7%)                    
  No                      195 (68.7%)                                                77 (71.3%)                    
  Enneking stages                                                                                                  
  I                       30 (10.6%)                                                 10 (9.3%)                     
  II                      213 (75%)                                                  79 (73.1%)                    
  III                     41 (14.4%)                                                 19 (17.6)                     

###### 

Allele and genotype frequency of single SNP association analysis in both stages.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  SNP\                   H-WE\       Allelic Frequency (%)   Allelic\    Adjusted\        Genotype Frequency (%)   Genotypic\   Adjusted\       OR^\*^95%CI                                            
  Affection              *P*-value                           *P*-value   *P*-value^\*^                             *P*-value    *P*-value^\*^                                                          
  ---------------------- ----------- ----------------------- ----------- ---------------- ------------------------ ------------ --------------- ------------- ---------------- ----------------------- -----------
  The Discovery Stage                                                                                                                                                                                  

  ***rs7023329***                    ***A***                 G                                                     AA           AG              GG                                                     

  OS                     0.759       56.69                   43.31       ***0.002033***   ***0.002908***           31.69        50.00           18.31         ***0.008446***   ***0.002885***          1.33

  CTR                    0.919       49.34                   50.66                        ***[0.049436]{.ul}***    24.26        50.15           25.59                          ***[0.049045]{.ul}***   1.13-1.62

  rs7027989                          G                       A                                                     GG           GA              AA                                                     

  OS                     0.348       78.35                   21.65       ***0.023912***   ***0.04427***            62.32        32.04           5.63          0.053070         ***0.07106***           1.50

  CTR                    0.997       82.52                   17.48                                                 68.09        28.85           3.06                                                   0.99-2.11

  The Validation Stage                                                                                                                                                                                 

  ***rs7023329***                    ***A***                 G                                                     AA           AG              GG                                                     

  OS                     0.743       57.87                   42.13       ***0.006589***   ***0.006737***           34.26        47.22           18.52         ***0.020154***   ***0.007089***          1.49

  CTR                    0.801       47.82                   52.18                        ***[0.047159]{.ul}***    22.61        50.42           26.97                          ***[0.049623]{.ul}***   1.11-2.00

  rs7027989                          G                       A                                                     GG           GA              AA                                                     

  OS                     0.853       77.78                   22.22       0.105079         0.1054                   60.19        35.19           4.63          0.120548         0.2914                  1.32

  CTR                    0.895       82.41                   17.59                                                 67.84        29.15           3.02                                                   0.79-2.21
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

OS: osteosarcoma; CTR: control; CI: confidence interval; OR: odds ratio.

Risk allele and significant *P* values were in italic bold, and corrected *P* values were underlined after Bonferroni correction. OR referred to the risk allele odds ratio in cases and controls.

\* Obtained in logistic regression models with adjustment for age, gender and family history.

###### 

Relationship between genotypes of rs7023329 within MTAP gene and clinicopathological features of patients with osteosarcoma.

  rs7023329               The Discovery Stage   The Validation Stage                                          
  ----------------------- --------------------- ---------------------- ---- ----- ------- ---- ---- ---- ---- -------
  Mean age (years)                              90                     52   142   0.695        37   20   51   0.796
  ≤20                     165                   55                     28   82    61      21   10   30        
  \>20                    119                   35                     24   60    47      16   10   21        
  Gender                                                                          0.968                       0.854
  Male                    146                   47                     26   73    56      20   11   25        
  Female                  138                   43                     26   69    52      17   9    26        
  Cancer family history                                                           0.104                       0.849
  Yes                     81                    23                     10   48    70      25   12   33        
  No                      203                   67                     42   94    38      12   8    18        
  Tumor location                                                                  0.459                       0.713
  Long tubular bones      231                   77                     41   113   83      32   11   40        
  Axial skeleton          53                    13                     11   29    25      5    9    11        
  Pathological fracture                                                           0.983                       0.314
  Yes                     55                    18                     10   27    23      6    4    13        
  No                      229                   72                     42   115   85      31   16   38        
  Metastasis                                                                      0.157                       0.483
  Yes                     89                    33                     11   45    31      8    6    17        
  No                      195                   57                     41   97    77      29   14   34        
  Enneking stages                                                                 0.118                       0.358
  I                       30                    12                     8    10    10      5    2    3         
  II                      213                   65                     41   107   79      24   17   38        
  III                     41                    13                     3    25    19      8    1    10        

###### 

Haplotypes frequency and association analyses.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Haplotype             Frequency (%) in the discovery stage           Frequency (%) in the validation stage                                                             
  --------------------- -------------------------------------- ------- --------------------------------------- ---------------- ------- ---------------- --------------- -----------------
  rs7023329-rs7027989   OS                                     CTR     *P*-value ^1^                           Global *P*^2^    OS      CTR              *P*-value ^1^   Global *P*^2^

  AG                    53.85                                  48.59   0.02729***\****                         ***\<0.0001***   52.51   46.90            0.12843         ***\<0.0001***\

  GG                    24.50                                  33.93   ***\<0.0001***                          25.27            35.52   ***0.00343***                    

  GA                    18.81                                  16.73   0.24745                                 16.86            16.66   0.94181                          

  AA                    2.85                                   0.75    ***\<0.0001***                          5.36             0.93    ***\<0.0001***                   
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

OS: osteosarcoma; CTR: control. Haplotypes in italics were the significant ones in the study, and significant *P* values were in italic bold.

1\. Based on 10000 permutations. 2. Based on comparison of frequency distribution of all haplotypes for the combination of SNPs.

\* The *P*-value could not be significant after Bonferroni correction (corrected P = 0.02729×4 = 0.10916).
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